Back to top

Image: Shutterstock

Masimo (MASI) Strengthens Global Footprint With New Launch

Read MoreHide Full Article

Masimo Corporation (MASI - Free Report) recently received the CE mark for its SafetyNet Alert and introduced the same in western Europe. Masimo SafetyNet Alert is an arterial blood oxygen saturation monitoring and alert system developed for utilization in a home setting. This system features Signal Extraction Technology (SET) wearable fingertip pulse oximetry sensor that offers wireless communication to an accompanying Home Medical Hub and smartphone app.

Masimo SafetyNet Alert tracks blood oxygen saturation (SpO2) and pulse rate (PR) by utilizing clinically proven Masimo SET Measure-through Motion and Low Perfusion pulse oximetry and perfusion index (Pi).

It is worth mentioning that Masimo SafetyNet Alert has not yet received the FDA 510(k) clearance and is unavailable for sale in the United States.

This launch is likely to provide a further boost to Masimo’s already strong product portfolio.

Significance of the Launch

For investors’ note, opioids are powerful painkillers that are commonly used as part of the recovery process post surgery and administered to patients suffering from chronic pain. However, these painkillers can also slow or stop one’s breathing that might lead to heart attack, brain damage and even death. An estimated number of above 100,000 people, globally, die each year from opioid overdose.

Zacks Investment Research
Image Source: Zacks Investment Research

Masimo SafetyNet Alert provides the breakthrough Masimo SET pulse oximetry, which is utilized in hospitals worldwide, in a home setting. On the basis of clinical proof, SET has enabled care teams to boost patient safety and outcomes.

This newly launched system offers escalating alerts when there are drops in oxygen levels and has been developed to wake up the person suffering from opioid overdose. If they do not wake up, the system sends alerts to others when help might be required.

Market Prospects

Per a report by Market Research Future, the global non-invasive monitoring device market is anticipated to witness a CAGR of 6.8% and is estimated to reach $21.59 billion by 2023. Rising adoption of non-invasive technology, and increasing prevalence of cardiovascular and neurovascular diseases are driving this market’s growth. Hence, this launch is well-timed for Masimo.

Recent Developments

This month, Masimo announced the findings of a study published in the Turkish Journal of Emergency Medicine, wherein researchers explored the utility of noninvasive, continuous Masimo Pleth Variability Index (PVi) when it comes to monitoring volume status and changes in spontaneously breathing patients who are undergoing hemodialysis (HD). Per the findings, a strong correlation has been found between change in PVi and the volume of fluid removed.

Again, this month, the company announced the findings of a study, published in the Journal of Pain & Relief, wherein researchers explored the utility of Masimo Bridge in reducing postoperative opioid needs in patients undergoing kidney donor surgery. Based on the positive outcomes, researchers concluded that Bridge may represent a complementary approach to lower postoperative opioid requirement.

In July, the company announced the release of its latest and most-advanced rainbow SET board, MX-7. The board has been engineered for integration into numerous multi-parameter monitors, which are available from the company’s various original equipment manufacturing (“OEM”) partners.

Price Performance

Shares of the company have gained 23.6% in the past year compared with the industry’s growth of 10.7%.

Zacks Rank & Key Picks

Currently, Masimo carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , Envista Holdings Corporation (NVST - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Henry Schein’s long-term earnings growth rate is estimated at 13.9%.

Envista Holdings’ long-term earnings growth rate is estimated at 27.4%.

Merit Medical’s long-term earnings growth rate is projected at 13.6%.